Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Post by Moneymagnet14on Sep 25, 2014 11:04am
215 Views
Post# 22969593

Insider Report:Craig Scheider has been buying CAN

Insider Report:Craig Scheider has been buying CAN Here's a link to the Canadian insider report and as you will see Craig has recently been buying CAN which is great to see. https://www.canadianinsider.com/node/7?menu_tickersearch=Cannabis+Technologies+Inc.+%7C+CAN Filings by Transaction Date Filings by Filing Date Filings by Insider Biz Brief Latest 10 SEDI filings (by transaction date) for CAN within the last 6 months [?] Amended Filing As of 11:59pm ET September 24th, 2014 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Price Sep 24/14 Sep 24/14 Schneider, Craig Douglas Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $0.210 Sep 24/14 Sep 24/14 Schneider, Craig Douglas Direct Ownership Common Shares 10 - Acquisition in the public market 25,000 $0.200 Sep 24/14 Sep 24/14 Schneider, Craig Douglas Direct Ownership Common Shares 10 - Acquisition in the public market 20,000 $0.195 Sep 23/14 Sep 23/14 Schneider, Craig Douglas Direct Ownership Common Shares 10 - Acquisition in the public market 20,000 $0.200
Bullboard Posts